trending Market Intelligence /marketintelligence/en/news-insights/trending/kqrch0wswkwo7przlriwja2 content esgSubNav
In This List

Allergan issues voluntary recall of sample packs of contraceptive drug in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergan issues voluntary recall of sample packs of contraceptive drug in US

Allergan PLC issued a voluntary recall of a particular lot of physician sample packs of its contraceptive medicine Taytulla that were given out to physicians in the U.S. market.

The Irish drug giant had recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of Taytulla.

Allergan said the pack contained four nonhormonal placebo capsules instead of active capsules.

As a result of this packaging error, oral contraceptive capsules that are taken out of sequence may place the user at risk for contraceptive failure and unintended pregnancy, according to the company. The reversing of the order may not be apparent to either new users or previous users of the product, increasing the likelihood of taking the capsules out of order.

The company said it is notifying customers by recall letter and is arranging for return of the particular sample packs with the lot number 5620706.